FDA has approved lucinactant (Surfaxin, Discovery Labs) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine.
FDA has approved lucinactant (Surfaxin, Discovery Labs) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine.
Discovery Labs anticipates that Surfaxin will be commercially available in the United States late this year.
"The approval of Surfaxin represents the first synthetic, peptide-containing surfactant product in the category," Thomas F. Miller, chief operating officer, Discovery Labs, told Formulary. "History has shown us that most therapeutic categories that begin with animal-derived medications ultimately evolve to new synthetic alternatives."
In addition, a recent independent, peer-reviewed study by Donn et. al. pointed toward a clear preference for synthetic alternatives to animal-derived medications by both neonatologists and parents of children in the NICU, according to Miller.
RDS is a condition in which premature infants are born with an insufficient amount of pulmonary surfactant, a substance produced naturally in the lungs and essential for breathing. Today, infants with RDS often require animal-derived surfactant replacement therapy along with mechanical ventilation to survive. Approximately 90,000 premature infants in the United States are treated annually with currently available animal-derived surfactants.
Surfaxin is the fifth drug approved in the United States to treat RDS in premature infants. The other FDA-approved surfactants are beractant (Survanta, Abbott), poractant alpha (Curosurf, Chiesi Limited), and calfactant (Infasurf, Ony/Forest Pharmaceuticals), and colfosceril palmitate (Exosurf, Glaxo Wellcome), which is no longer marketed.
The safety and efficacy of Surfaxin for the prevention of RDS in premature infants was demonstrated in a large, multinational phase 3 clinical program that included 1,294 patients. Within 30 minutes of birth, infants in the study received either Surfaxin, Exosurf, or Survanta. Surfaxin and Exosurf served as the primary comparison for this study; Survanta served as another comparison. Surfaxin demonstrated significant improvement in both RDS at 24 hours after birth and RDS-related mortality through 2 weeks, when compared with Exosurf.
Surfaxin should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving Surfaxin should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.
Most common adverse reactions associated with the use of Surfaxin are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During Surfaxin administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. Surfaxin is not indicated for use in acute RDS.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.